Yale University

New Haven, Connecticut
Milton Harris 29’ Professor of Chemistry
Professor of Molecular, Cellular and Developmental Biology


Dr. Alanna Schepartz has developed anti-cancer drugs called beta-peptide inhibitors to address one of the biggest challenges in drug discovery — how to block “protein-protein interactions” within cells that are closely related to diseases such as Alzheimer’s and cancer. Many proteins that cause disease simply to bind to other proteins inside the cell. Proteins that function in this way are said to participate in “protein-protein interactions”. Protein drugs almost without exception carry out their tasks outside the cell, not within. The beta-peptide inhibitors developed by Dr. Schepartz represent a new generation of anti-cancer drugs that are highly effective and specific in targeting almost any cancer-related protein-protein interaction. This new class of drugs may positively impact the treatment of almost half of all cancers. The Schepartz laboratory synthesized a series of peptide molecules that may provide a new therapeutic approach to inhibit EGFR — an important protein that is often mutated in non-small cell lung cancer. The molecules can be used to inhibit even those forms of EGFR that are resistant to current therapies. Continued development of these new therapeutic agents could lead to new and more effective ways of treating patients whose lung cancer has already developed resistance to current therapies.


Dr. Alanna Schepartz received her B.S. from State University of New York, Albany, NY and her Ph.D. at Columbia University. She then conducted postdoctoral work at the California Institute of Technology. She joined the faculty at Yale in 1988 as an Assistant Professor, was promoted to the rank of Full Professor in 1995, and was named a Sterling Professor in 2017. In 2019, Alanna moved to the University of California, Berkeley where she is now the C.Z. and Irmgard Chu Distinguished Chair of Chemistry and Professor of Molecular and Cell Biology. She is also a Faculty Affiliate of the California Institute for Quantitative Biosciences (QB3).

From 1991 to 2004, Dr. Schepartz co-directed the NFCR Center for Protein and Nucleic Acid Chemistry and from 2005 to 2010 she directed the NFCR Center for Anti-Cancer Drug Design and Discovery. She is an elected member of the National Academy of Sciences and a Fellow of the American Chemical Society. She is the recipient of numerous awards including the Ralph F. Hirschmann Award in Peptide Chemistry, Wheland Medal, and the inaugural recipient of the ACS Chemical Biology Prize.

Alanna Schepartz has also received numerous awards for teaching and service to the community. She served as Associate Editor of the Journal of the American Chemical Society and is Editor-in-Chief of the classic ACS journal Biochemistry.

Areas of Focus

Cancer Types

Years of NFCR Funding

1991 to 2014

Related Content

Newly Diagnosed Brain Tumor Patients Should Consult Their Doctors Before Starting the Preventive Anti-Epileptic Treatment

Bone Cancer 101

New Brain Scan Technology Can Improve Tumor Removal

Any illness or disease that impacts the brain is highly complex. None more so than brain tumors, which affect over 20,000 Americans each year. While surgeons have become more advanced in the removal of brain tumors, experts continue to face extreme challenges in ensuring all cancerous tissues are removed during surgery. That is, until now.  A recent study found a high-intensity focused ultrasound 2.5 times more effective at identifying cancerous tissue than surgeons alone and significantly better than traditional ultrasound. The newly identified ultrasound cancer treatment technique is referred to as shear wave elastography.  Shear wave elastography measures the stiffness and stretch within the tissue, with vibrations moving faster through stiffer tissue. Brain tumors tend to be stiffer than normal brain tissue, allowing the new method to map suspicious areas of particular stiffness. In the study, researchers compared this high-intensity focused ultrasound to the standard ultrasound cancer treatment and a surgeon’s opinion regarding which tissues to remove.  The study used these three different techniques on a total of 26 patients. All of the techniques were compared with gold-standard MRI scans after the surgery – which while effective, are exceptionally time-consuming and expensive.  While the shear wave elastography ultrasound cancer treatment proved to be the most effective with 94% sensitivity (compared to 73% for the standard ultrasound tumor removal and 36% for the surgeon’s opinion), researchers concluded that the shear wave scans may yield more false positives than surgeons.  Ensuring all of a brain tumor is removed without damaging healthy tissue is a major challenge in brain surgery. This new type of scan can greatly increase a surgeon’s confidence that no cancer tissue is left behind in surgery.  The use of this unique ultrasound in cancer treatment makes a significant stride towards improving the health outlook for brain cancer patients. The National Foundation for Cancer Research (NFCR) is also providing new hope in the realm of brain cancer through its partnership with Global Coalition for Adaptive Research (GCAR). GCAR is a nonprofit organization comprised of some of the world’s foremost physicians, clinical researchers and investigators united in expediting the discovery and development of cures for patients with rare and deadly diseases. GCAR is the official sponsor of GBM AGILE, an adaptive platform trial for patients with glioblastoma (GBM) – the most common and deadliest of malignant primary brain tumors. The GBM AGILE has been developed with a revolutionary approach to defeating GBM, with the goal of enabling faster and more efficient testing of new agents and combination therapies, better identification of predictive and prognostic biomarkers and delivery of more effective treatments to all glioblastoma patients. GBM AGILE is an innovative approach for treating brain cancer, providing new hope where little existed before. NFCR continues to fund innovative researchers paving the way to finding new screening methods, treatments, and cures for all cancers, including brain cancer. To learn more about the progress that NFCR-funded scientists are making in the way of brain cancer, visit the NFCR Brain Cancer page.  Additional Reads You May Enjoy: “Pink Drink” to Aid Brain Tumor Treatment Treating Brain Cancer: What You Need to Know GBM AGILE – Changing the Way We Fight Brain Cancer Stay connected with us! […]